- Home
- VINP vs PRTA Comparison
VINP vs PRTA Comparison
Compare VINP & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- PRTA
- Stock Information
- Founded
- VINP 2009
- PRTA 2012
- Country
- VINP Brazil
- PRTA Ireland
- Employees
- VINP N/A
- PRTA N/A
- Industry
- VINP Investment Managers
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- PRTA Health Care
- Exchange
- VINP Nasdaq
- PRTA Nasdaq
- Market Cap
- VINP 641.7M
- PRTA 765.2M
- IPO Year
- VINP 2021
- PRTA N/A
- Fundamental
- Price
- VINP $10.11
- PRTA $15.56
- Analyst Decision
- VINP Strong Buy
- PRTA Buy
- Analyst Count
- VINP 2
- PRTA 8
- Target Price
- VINP $13.50
- PRTA $46.00
- AVG Volume (30 Days)
- VINP 64.8K
- PRTA 336.3K
- Earning Date
- VINP 02-26-2025
- PRTA 02-20-2025
- Dividend Yield
- VINP 6.92%
- PRTA N/A
- EPS Growth
- VINP N/A
- PRTA N/A
- EPS
- VINP 0.60
- PRTA N/A
- Revenue
- VINP $88,217,697.00
- PRTA $135,157,000.00
- Revenue This Year
- VINP $17.69
- PRTA $56.89
- Revenue Next Year
- VINP $50.55
- PRTA N/A
- P/E Ratio
- VINP $16.90
- PRTA N/A
- Revenue Growth
- VINP 9.03
- PRTA 47.92
- 52 Week Low
- VINP $9.01
- PRTA $11.70
- 52 Week High
- VINP $11.85
- PRTA $31.03
- Technical
- Relative Strength Index (RSI)
- VINP 44.04
- PRTA 59.65
- Support Level
- VINP $10.42
- PRTA $13.69
- Resistance Level
- VINP $10.86
- PRTA $15.09
- Average True Range (ATR)
- VINP 0.21
- PRTA 0.91
- MACD
- VINP -0.03
- PRTA 0.13
- Stochastic Oscillator
- VINP 12.87
- PRTA 68.56
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).